Why PCOS Is Now PMOS: Key Updates for Modern OBGYNs
Polycystic ovary syndrome has officially transitioned to a new diagnostic terminology. Consequently, understanding PMOS in clinical practice is vital for healthcare providers managing reproductive and endocrine health. An international consensus process involving 56 medical organizations established this historic name change. Specifically, the new designation of polyendocrine metabolic ovarian syndrome corrects a longstanding misnomer. The classic ovarian morphology reflects arrested antral follicles rather than pathologic cysts. Therefore, clinicians must reframe how they evaluate and treat this complex condition across a patient's lifespan.
Why the Renaming to PMOS Matters
Historically, the legacy name focused attention solely on fertility and ovarian morphology. However, PMOS represents a lifelong multisystem disorder driven by insulin resistance and hormonal dysregulation. In addition, the condition affects approximately 10% to 13% of reproductive-age individuals worldwide. Many women experience delayed diagnoses because they lack prominent ovarian cysts on imaging. Furthermore, the previous terminology obscured severe cardiometabolic, dermatologic, and psychological complications. As a result, adopting the new terminology helps clinicians identify early systemic risks before metabolic dysfunction progresses.
PMOS in Clinical Practice and Obstetric Risk Management
During pregnancy, PMOS significantly elevates maternal and fetal risks. For instance, affected patients experience higher rates of gestational diabetes and hypertensive disorders. Moreover, recent evidence shows elevated risks for preterm delivery, cesarean birth, and fetal growth restriction. These adverse outcomes often persist after adjusting for maternal body mass index and age. Therefore, clinicians must document PMOS as an active risk modifier during the first prenatal visit. Additionally, care teams should integrate targeted metabolic surveillance and blood pressure monitoring throughout gestation, which can be further explored through a dedicated Advanced Clinical Practice Program In Fetal Medicine.
Diagnostic Criteria and Long-Term Surveillance
Crucially, the formal diagnostic criteria remain unchanged despite the updated name. Clinicians still require at least two of three established features in adults. First, patients may present with irregular menstrual cycles or ovulatory dysfunction. Second, clinicians evaluate clinical or biochemical hyperandrogenism. Third, imaging shows polycystic ovarian morphology or elevated anti-Müllerian hormone levels. In contrast to diagnostic continuity, routine surveillance pathways must expand significantly. Thus, providers should regularly screen patients for dyslipidemia, glucose intolerance, and emotional distress, core competencies enhanced by completing a comprehensive Certification Course In Diabetes And Metabolic Disorder Care.
Frequently Asked Questions
Q1: Why was PCOS renamed to PMOS?
The new name eliminates confusion surrounding ovarian cysts and emphasizes the systemic endocrine-metabolic nature of the disorder.
Q2: Did the diagnostic criteria change with the new PMOS nomenclature?
No, the diagnostic criteria remain unchanged and require at least two of the three classic features for adult diagnosis.
Q3: How does PMOS impact obstetric outcomes?
PMOS increases the risk of gestational diabetes, preeclampsia, preterm birth, and fetal growth restriction during pregnancy, all of which are critical topics covered within specialized Obstetrics Gynecology And Womens Health Speciality Courses.
References
- Khomami MB et al. From Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS): What Obstetricians and Gynecologists Need to Know. Am J Obstet Gynecol. 2026 Aug 28. doi: undefined. PMID: 42665241.
- Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026.
